Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

doi:10.1056/NEJMoa2404139

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

The New England journal of medicine - 7 Nov 2024

Long Georgina V, Hauschild Axel, Santinami Mario, Kirkwood John M, Atkinson Victoria, Mandala Mario, Merelli Barbara, Sileni Vanna Chiarion, Nyakas Marta, Haydon Andrew, Dutriaux Caroline, Robert Caroline, Mortier Laurent, Schachter Jacob, Schadendorf Dirk, Lesimple Thierry, Plummer Ruth, Larkin James, Tan Monique, Adnaik Sachin Bajirao, Burgess Paul, Jandoo Tarveen, Dummer Reinhard

Abstract excerpt

BACKGROUND: The 5-year results of this trial showed that adjuvant therapy with dabrafenib plus trametinib resulted in longer relapse-free survival and distant metastasis-free survival than placebo among patients with BRAF V600-mutated stage III melanoma. Longer-term data were needed, including data regarding overall survival. METHODS: We randomly assigned 870 patients with resected stage III melanoma with BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Double-Blind Method

Share to Imidazoles

Share to Kaplan-Meier Estimate

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed

Identifiers

PMID: 38899716
DOI: 10.1056/NEJMoa2404139

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.PMID 38899716Read ↗

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.Semantic proximity Read ↗

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.Semantic proximity Read ↗

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.Semantic proximity Read ↗

Improved overall survival in melanoma with combined dabrafenib and trametinib.Semantic proximity Read ↗

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.Semantic proximity Read ↗

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.Semantic proximity Read ↗

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.Semantic proximity Read ↗

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.Semantic proximity Read ↗

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.Semantic proximity Read ↗

Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: A systematic review and network meta-analysis.Semantic proximity Read ↗

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.Semantic proximity Read ↗

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.